HER2-positive breast cancer used to be one of the more dangerous kinds, because it tends to grow and spread fast.1PubMed Central. Targeted therapeutic options and future perspectives for HER2-positive breast cancer Drugs aimed directly at HER2 have improved survival so much that today’s outlook bears little resemblance to older statistics.2PubMed Central. Targeted therapeutic options and future perspectives for HER2-positive breast cancer Most people with early-stage disease now do very well, with about 9 in 10 or more alive and cancer-free a decade later in favorable cases, and people whose cancer has spread often live four to five years or longer.
Why HER2 Once Meant a Worse Outlook
HER2 is a protein on the surface of cells that, when switched on, tells cells to grow and survive.3PubMed. HER2 in breast cancer: a review and update In about 15 to 20 out of 100 breast cancers, the cells carry extra copies of the HER2 gene and make far too much of this protein. These tumors grow aggressively and responded poorly to standard chemotherapy alone.4PubMed Central. Targeted therapeutic options and future perspectives for HER2-positive breast cancer The cancer stays dependent on HER2 at every stage, so blocking it attacks something the tumor cannot do without.5PubMed Central. Molecular Pathways and Mechanisms of HER2 in Cancer Therapy
You find out you are HER2-positive from the biopsy. A pathologist tests the tumor tissue for the HER2 protein, and your report scores the staining from 0 to 3+, with 3+ counting as positive. A borderline 2+ result gets a second, gene-level test to settle the answer.
HER2-positive describes the tumor’s biology, not its stage. A very small tumor and a large one can both be HER2-positive, so the label alone says nothing about how far the cancer has spread. It is also not inherited the way a BRCA gene change is. The extra HER2 copies arise in the tumor cells themselves, so relatives do not inherit a risk from your result, and nothing you did caused it.
Trastuzumab (brand name Herceptin) is an antibody drug that latches onto HER2. Adding it to chemotherapy for early cancer cut the 10-year risk of the cancer coming back by about a third.6PubMed Central. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials About 9 more people in every 100 stayed free of cancer for 10 years, and about 6 more in every 100 avoided dying of breast cancer.7PubMed Central. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials It did not raise deaths from other causes.8PubMed Central. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
Survival Rates for Early-Stage HER2-Positive Cancer
For small HER2-positive tumors that have not reached the lymph nodes, a gentler regimen of paclitaxel plus trastuzumab is standard.9PubMed Central. HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation? After 10 years on it, about 94 in 100 were alive and about 99 in 100 had not died of breast cancer.10PubMed Central. HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation? About 96 in 100 never had the cancer return in the breast area or elsewhere over 10 years.11PubMed Central. HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation? This held whether or not the tumor was also hormone-receptor positive.12PubMed Central. HER2-Positive Early Breast Cancer: Time for Ultimate De-Escalation? Serious heart failure on this regimen occurred in only about 1 in 200.13PubMed Central. Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer The two survival figures differ because overall survival counts deaths from any cause, while breast-cancer-specific survival counts only deaths from this cancer.
The lighter plan uses weekly paclitaxel with trastuzumab for about 12 weeks, followed by trastuzumab alone to complete about a year of HER2 treatment. It leaves out the anthracycline drugs, which carry a heart risk and a small risk of later blood cancers. Paclitaxel commonly causes hair thinning, tingling or numbness in the hands and feet, and tiredness. Report the tingling early, since doses can be adjusted. Whether you qualify depends on your tumor size and node status, so ask your oncologist rather than assuming.
Larger tumors or cancer in the lymph nodes usually get stronger combinations of chemotherapy and HER2 drugs. Tumor size and node spread remain the biggest factors in early-stage outlook.14PubMed Central. Trastuzumab for early-stage, HER2-positive breast cancer: a meta-analysis of 13 864 women in seven randomised trials
A 10-year rate counts people alive 10 years after treatment began, so it reflects treatments from years ago, and current results may be better. It also describes a group, not your own fate. Your oncologist can tell you which numbers match your stage and plan.
Why Response to Treatment Before Surgery Matters
Many people get HER2 drugs and chemotherapy before surgery to shrink the tumor. When the surgeon removes tissue and no invasive cancer remains, your report may call it a pathologic complete response, or pCR.15PubMed. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis People with no cancer left at surgery have much longer times before any recurrence and longer lives.16PubMed. Association of Pathologic Complete Response to Neoadjuvant Therapy in HER2-Positive Breast Cancer With Long-Term Outcomes: A Meta-Analysis17PubMed Central. Pathologic complete response to neoadjuvant chemotherapy with trastuzumab predicts for improved survival in women with HER2-overexpressing breast cancer
Giving drugs first lets doctors see in real time whether the tumor shrinks, which tells them the cancer is sensitive to the treatment. Shrinking it can make surgery smaller, and sometimes makes breast-conserving surgery possible when it otherwise would not be. Giving drugs first does not lower the chance of cure compared with giving them after surgery; it mainly adds information. Your team may use scans or exams during treatment to track the shrinkage.
Leftover cancer at surgery does not mean treatment has failed for good. Doctors usually switch to a different HER2 drug afterward, and trastuzumab emtansine is commonly used in this situation.
People with no cancer left at surgery may be able to skip further chemotherapy and continue antibody drugs alone.18PubMed Central. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer In one trial nearly all stuck with that lighter plan and none had recurrence at about 19 months.19PubMed Central. A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancer Follow-up was short, so this remains an option to discuss rather than a standard.
Hormone Receptors and Triple-Positive Cancer
Triple-positive means the cancer is HER2-positive and also has estrogen and progesterone receptors. Hormone receptor status likely splits HER2-positive cancer into two subtypes that behave differently.20PubMed. Triple positive breast cancer: a distinct subtype? In one large registry, triple-positive patients lived longer than those with HER2-positive, hormone-negative cancer.21Journal of Breast Cancer. Clinical Differences in Triple-Positive Operable Breast Cancer Subtypes in Korean Patients: An Analysis of Korean Breast Cancer Registry Data But the HER2 and estrogen signals cross-talk, which can blunt both HER2 drugs and hormone therapy.22PubMed Central. Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study So triple-positive cancer is usually treated with both HER2 drugs and hormone therapy.
Hormone therapy, such as tamoxifen or an aromatase inhibitor, blocks or lowers the estrogen signal, a separate growth pathway from HER2. HER2 drugs alone leave that pathway free to feed the cancer. The pills are taken daily by mouth and usually start after chemotherapy ends, alongside continuing HER2 treatment. Which one you take often depends on whether you have gone through menopause. Hormone-positive cancers can return many years later, which is why the pills often continue five years or longer.
Survival When HER2-Positive Cancer Has Spread
The usual first treatment for spread cancer combines pertuzumab, trastuzumab and docetaxel chemotherapy. Half of people on this combination lived at least 56.5 months, nearly 5 years.23PubMed Central. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer That is about 16 months longer than without pertuzumab.24PubMed Central. Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer Median survival is the point when half the group is still alive, so many people live well beyond it.
When cancer grows again, trastuzumab deruxtecan (Enhertu) is the standard next step.25PubMed. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial It held cancer in check for a midpoint of 29 months, versus about 7 months with the older drug.26PubMed Central. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial Half of people lived at least 52.6 months on it.27PubMed Central. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial In heavily pretreated patients, about 6 in 10 saw tumors shrink.28PubMed Central. Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
Treatment is given in lines. A line is one drug or combination used until it stops working or side effects become too much, after which the next is started. HER2-positive cancer has several effective lines, which is a major reason survival has lengthened. The order is guided by what has worked, what side effects you have had, and where the cancer is.
Brain Metastases and HER2-Positive Cancer
Trastuzumab controls cancer in the body well but struggles to cross the protective barrier around the brain.29PubMed Central. Brain Metastases in HER2-Positive Breast Cancer: Current and Novel Treatment Strategies Some tablet drugs are small enough to get in.30PubMed Central. Tyrosine kinase inhibitors in HER2‐positive breast cancer brain metastases: A systematic review and meta‐analysis Adding tucatinib to trastuzumab and capecitabine cut the risk of death by about half in people with growing brain tumors.31PubMed Central. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial A year later, about 72 in 100 were alive on tucatinib versus 41 in 100 without it.32PubMed Central. Intracranial Efficacy and Survival With Tucatinib Plus Trastuzumab and Capecitabine for Previously Treated HER2-Positive Breast Cancer With Brain Metastases in the HER2CLIMB Trial
Brain spread is more common in HER2-positive cancer than in some other breast cancer types. Drugs can keep the body disease well controlled while the brain becomes the place where cancer grows, since some drugs reach it poorly. Some centers do periodic brain MRI scans in people with metastatic disease, and it is worth asking whether this applies to you.
Radiation or surgery is often used alongside drugs, and the drug choice depends on whether brain tumors are growing. Trastuzumab deruxtecan also shows activity in the brain. Report new persistent headaches, weakness, balance problems, vision changes, seizures, or confusion promptly rather than waiting for the next visit.
Other Factors That Shape Your Outlook
Some tumors are crowded with immune cells, which a pathologist can measure.33PubMed Central. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges More immune cells predict better response before surgery and longer cancer-free survival.34PubMed Central. Tumor-infiltrating lymphocytes in HER2-positive breast cancer: potential impact and challenges In spread disease, such tumors stayed controlled a median 49 months versus 18.5 months.35PubMed Central. Prognostic impact of tumor-infiltrating lymphocytes in HER2+ metastatic breast cancer receiving first-line treatment
On a report, these appear as tumor-infiltrating lymphocytes, reported as a percentage of the tissue around the tumor. Higher is associated with better outcomes, but a low count does not mean your treatment will fail, since most people with low counts are still treated successfully. It adds to the picture alongside size, nodes, and receptors. Some tumors learn to grow despite trastuzumab through gene changes such as PIK3CA mutations.36PubMed Central. Resistance to Trastuzumab in Breast Cancer Not all reports list it and it is not yet used to choose treatment routinely, but you can ask whether it was measured.
Older women are often undertreated and have more recurrence.37PubMed Central. Triple-negative and Her2-positive breast cancer in women aged 70 and over: prognostic impact of age according to treatment Heart disease is common in older patients and raises side-effect risk.38PubMed. HER2-targeted treatment for older patients with breast cancer: An expert position paper from the International Society of Geriatric Oncology Black patients had about 14% higher risk of death than White patients, in part from lower response rates.39PubMed Central. Racial and ethnic disparities in neoadjuvant chemotherapy patterns and outcomes in early-stage HER2-positive breast cancer High out-of-pocket costs can lead people to skip treatment, worsening outcomes.40PubMed Central. Financial toxicity and implications for cancer care in the era of molecular and immune therapies
If cost is a worry, ask for a hospital financial counselor early. Drug makers run copay assistance programs. Never skip doses to save money without telling your team.
Protecting Your Heart During Treatment
Trastuzumab can reduce how strongly the heart pumps, most often in the first 6 months.41The Journal of Hematology Oncology Pharmacy. HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer So heart pumping is checked before treatment and about every 3 months during it, usually by echocardiogram.42The Journal of Hematology Oncology Pharmacy. HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer Risk is higher after anthracycline chemotherapy like doxorubicin.43The Journal of Hematology Oncology Pharmacy. HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer The weakness usually recovers 1 to 3 months after stopping the drug.44The Journal of Hematology Oncology Pharmacy. HER2 Heartbreak? Understanding the Management of Cardiotoxicity From Trastuzumab in HER2-Positive Breast Cancer
An echocardiogram is a painless ultrasound of the heart that takes about 30 to 45 minutes. Your report lists the ejection fraction, the share of blood pumped per beat. A drop may pause treatment until it recovers. Tell your team about shortness of breath on light activity or when lying flat, swollen ankles or sudden weight gain, and a racing or irregular heartbeat.
HER2-Low Is Not the Same as HER2-Positive
Tumors with a 1+ or 2+ score without extra gene copies are now called HER2-low.45PubMed. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials They are distinct from HER2-zero tumors in biology and prognosis.46PubMed. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials New drugs such as trastuzumab deruxtecan are being used for this group.47PubMed Central. HER2-Low Breast Cancer: Molecular Characteristics and Prognosis The figures in this article do not apply to it.
HER2-low is treated as HER2-negative for most early treatment. Ask whether your score is 0, 1+, 2+, or 3+, since it matters if the cancer later spreads.